Lexicon Pharma (LXRX): PDUFA Date Extension A Speedbump, First Pass Approval Still Likely - Wedbush
Get Alerts LXRX Hot Sheet
Rating Summary:
3 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Join SI Premium – FREE
Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Lexicon Pharmaceuticals (NASDAQ: LXRX). The analyst believes the three month PDUFA date delay for telotristat etiprate in carcinoid syndrome is minor and no announcement of an advisory committee meeting is a positive signal for the approval chances of the drug. Given the robustness of the data package, the analyst continues to expect first pass approval.
No change to the price target of $33.
For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.
Shares of Lexicon Pharmaceuticals closed at $18.83 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Craig-Hallum Assumes Guardant Health (GH) at Buy, 'We think that GH is undervalued'
- Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
- GATX Corp. (GATX) PT Raised to $137 at TD Cowen
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDARelated Entities
Liana Moussatos, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!